Understanding the microenvironment of disease is critical for the success of targeted therapies. For years, the complex landscape of the tumor microenvironment could only be studied in single-cell snapshots by flow cytometry or limited tissue staining. Advanced multiplexing technologies such as Imaging Mass Cytometry™ (IMC™) now enable the imaging of up to 40 protein markers on both the cellular and tissue level.
This webcast explores the need to employ multidimensional methods for immunophenotyping of cancer immune microenvironments. The speakers will highlight the importance and value of employing image-based methods that preserve tissue context in opposition to single-cell approaches. They will also describe the fundamental methods for building a large antibody panel for high plex platforms and emphasize the importance of a variety of techniques available to facilitate antibody validation.
You will learn: The value of using image-based multiplex technologies that preserve tissue context compared to single-cell approaches. The essential methodological aspects of building a large panel for Imaging Mass Cytometry. Why antibody validation techniques are exceptionally important in high plex platforms and why no single assay is sufficient to verify antibody specificity.
Learn more about the power of Imaging Mass Cytometry.
Learn more about how CST can make your next IMC™ experiment a success.
Cell Signaling Technology and CST are registered trademarks of Cell Signaling Technology, Inc. All other trademarks are the property of their respective owners.